Search

Your search keyword '"Bernier, C."' showing total 608 results
Start Over Author "Bernier, C."
608 results on '"Bernier, C."'

1. French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis)

Author

Ingen-Housz-Oro, S., Matei, I., Gaillet, A., Gueudry, J., Zaghbib, K., Assier, H., Hua, C., Bensaid, B., Colin, A., Ouedraogo, R., Redlich, J., Courtois, E., Chazelas, K., Sbidian, E., Nakad, L., Bequignon, E., Terkmane, N., Gaultier, F., Schlemmer, F., Do-Pham, G., Barbaud, A., Lebrun-Vignes, B., Hoffmann, C., Mahé, P.-J., Le Floch, R., Bernier, C., Vabres, B., Milpied, B., Delcampe, A., Tétart, F., Tauber, M., Staumont-Sallé, D., Dezoteux, F., Descamps, V., Misery, L., Bursztejn, A.-C., Dereure, O., Amazan, E., Le Bidre, E., Le Pallec, S., Lagier, C., Laroche, A., Ferrat, E., Wolkenstein, P., and de Prost, N.

Published
2024
Full Text
View/download PDF

8. Sulphur-bearing molecules in diffuse molecular clouds: new results from SOFIA/GREAT and the IRAM 30 m telescope

Author

Neufeld, D. A., Godard, B., Gerin, M., Forêts, G. Pineau des, Bernier, C., Falgarone, E., Graf, U. U., Güsten, R., Herbst, E., Lesaffre, P., Schilke, P., Sonnentrucker, P., and Wiesemeyer, H.

Subjects
Astrophysics - Astrophysics of Galaxies
Abstract

We have observed five sulphur-bearing molecules in foreground diffuse molecular clouds lying along the sight-lines to five bright continuum sources. We have used the GREAT instrument on SOFIA to observe the 1383 GHz $^2\Pi_{3/2} J=5/2-3/2$ transitions of SH towards the star-forming regions W31C, G29.96-0.02, G34.3+0.1, W49N and W51, detecting foreground absorption towards all five sources; and the EMIR receivers on the IRAM 30m telescope at Pico Veleta to detect the H$_2$S 1(10)-1(01), CS J=2-1 and SO 3(2)-2(1) transitions. In nine foreground absorption components detected towards these sources, the inferred column densities of the four detected molecules showed relatively constant ratios, with N(SH)/N(H$_2$S) in the range 1.1 - 3.0, N(CS)/N(H$_2$S) in the range 0.32 - 0.61, and N(SO)/N(H$_2$S) in the range 0.08 - 0.30. The observed SH/H$_2$ ratios - in the range (0.5-2.6) $\times 10^{-8}$ - indicate that SH (and other sulphur-bearing molecules) account for << 1% of the gas-phase sulphur nuclei. The observed abundances of sulphur-bearing molecules, however, greatly exceed those predicted by standard models of cold diffuse molecular clouds, providing further evidence for the enhancement of endothermic reaction rates by elevated temperatures or ion-neutral drift. We have considered the observed abundance ratios in the context of shock and turbulent dissipation region (TDR) models. Using the TDR model, we find that the turbulent energy available at large scale in the diffuse ISM is sufficient to explain the observed column densities of SH and CS. Standard shock and TDR models, however, fail to reproduce the column densities of H$_2$S and SO by a factor of about 10; more elaborate shock models - in which account is taken of the velocity drift, relative to H$_2$, of SH molecules produced by the dissociative recombination of H$_3$S$^+$ - reduce this discrepancy to a factor ~ 3., Comment: 30 pages, accepted for publication in A&A

Published
2015
Full Text
View/download PDF

12. Intérêt d’une batterie spécialisée de tests épicutanés dans une cohorte de patients adressés pour hypersensibilité à leur implant orthopédique. Une étude multicentrique du DAG

Author

Gautier, C., Giordano-Labadie, F., Marcant, P., Castelain, F., Raison-Peyron, N., Milpied, B., Kurihara, F., Bara, C., Ferrier-Le Bouedec, M.C., Pasteur, J., Tetart, F., Assier, H., Morice, C., Bernier, C., Delaunay, J., Valois, A., Boulard, C., Crepy, M.N., Leleu, C., Chasset, F., Hardy, A., and Barbaud, A.

Published
2024
Full Text
View/download PDF

15. Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: french national audit of practices, literature review, and consensus agreement

Author

Thorel, D., Ingen-Housz-Oro, S., Royer, G., Delcampe, A., Bellon, N., Bodemer, C., Welfringer-Morin, A., Bremond-Gignac, D., Robert, M. P., Tauber, M., Malecaze, F., Dereure, O., Daien, V., Colin, A., Bernier, C., Couret, C., Vabres, B., Tetart, F., Milpied, B., Cornut, T., Ben Said, B., Burillon, C., Cordel, N., Beral, L., de Prost, N., Wolkenstein, P., Muraine, M., and Gueudry, J.

Published
2020
Full Text
View/download PDF

16. Impact du traitement par dupilumab sur les résultats des patch tests

Author

Boquel, S., primary, Soria, A., additional, Badaoui, A., additional, Marcant, P., additional, Bara, C., additional, Peyron, N. Raison, additional, Crepy, M.N., additional, Giordano-Labadie, F., additional, Amsler, E., additional, Milpied, B., additional, Delaunay, J., additional, Darrigade, A.S., additional, Pralong, P., additional, Boulard, C., additional, Bouedec, M.C. Ferrier Le, additional, Tauber, M., additional, Pasteur, J., additional, Valois, A., additional, and Bernier, C., additional

Published
2023
Full Text
View/download PDF

18. Eczémas paradoxaux sous biothérapies ciblant l’axe IL-5/IL-5R

Author

Bourdenet, V., primary, Devouassoux, G., additional, Beurnier, A., additional, Bernier, C., additional, Carpentier, O., additional, Chenivesse, C., additional, Du Thanh, A., additional, Gadiolet, Y., additional, Kelkel, E., additional, Larrousse, M., additional, Soria, A., additional, Staumont-Salle, D., additional, Streker, A., additional, Valois, A., additional, Blanc, F.X., additional, Freymont, N., additional, and Nosbaum, A., additional

Published
2023
Full Text
View/download PDF

20. Anaphylaxie au Gaviscon®

Author

Senkwenda Pandi, A.L., primary, Bernier, C., additional, El Hanache, H., additional, Veyrac, G., additional, and Colas, L., additional

Published
2023
Full Text
View/download PDF

26. Eczéma paradoxal sous biothérapie ciblant l’axe IL-5/IL-5R

Author

Bourdenet, V., primary, Devouassoux, G., additional, Antoine, B., additional, Bernier, C., additional, Carpentier, O., additional, Chenivesse, C., additional, Du Thanh, A., additional, Fry, S., additional, Gadiolet, Y., additional, Gamez, A.S., additional, Kelkel, E., additional, Larousse, M., additional, Soria, A., additional, Staumont-Sallé, D., additional, Streker, A., additional, Valois, A., additional, Xavier, B., additional, Freymont, N., additional, and Nosbaum, A., additional

Published
2022
Full Text
View/download PDF

28. Étude de survie du traitement par omalizumab dans une cohorte multicentrique française de patients atteints d’urticaire chronique

Author

Litovsky, J., primary, Paryl, M., additional, Hacard, F., additional, Tétart, F., additional, Boccon Gibod, I., additional, Dezoteux, F., additional, Staumont-Sallé, D., additional, Darrigade, A.S., additional, Doutre, M.S., additional, Milpied, B., additional, Soria, A., additional, Amsler, E., additional, Bernier, C., additional, Perrot, J.L., additional, Raison Peyron, N., additional, Mura, T., additional, Grosjean, J., additional, and Du Thanh, A., additional

Published
2022
Full Text
View/download PDF

29. Impact du traitement par dupilumab sur les résultats des patch-tests

Author

Bocquel, S., primary, Soria, A., additional, Badaoui, A., additional, Marcant, P., additional, Bara, C., additional, Raison Peyron, N., additional, Crépy, M.N., additional, Giordano-Labadie, F., additional, Amsler, E., additional, Milpied, B., additional, Delaunay, J., additional, Darrigade, A.S., additional, Pralong, P., additional, Boulard, C., additional, Ferrier Le Bouedec, M.C., additional, Tauber, M., additional, Pasteur, J., additional, Valois, A., additional, and Bernier, C., additional

Published
2022
Full Text
View/download PDF

34. Impact de la maladie thrombo-embolique chez les patients traités par Pembrolizumab en première ligne pour un cancer du poumon non à petites cellules, métastatique, PDL1 > 50%

Author

Doubre, H., primary, Huchot, E., additional, Simonneau, Y., additional, Roa, M., additional, Le Treut, J., additional, Le Garff, G., additional, Bylicki, O., additional, Schott, R., additional, Bravard, A.S., additional, Tiercin, M., additional, Lamy, R., additional, De Chabot, G., additional, Marti, A., additional, Moreau, D., additional, Locher, C., additional, Bernier, C., additional, Chouaid, C., additional, and Descourt, R., additional

Published
2022
Full Text
View/download PDF

44. CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition

Author

Yin Sy, Szychowski J, Natasha Chaudhary, Duffy Nm, Veloso A, Bowlan J, Stocco R, Papp R, Martino G, Singhania A, Rachel K. Szilard, Fourtounis J, Leclaire M, Liu B, Alejandro Álvarez-Quilón, de Rugy Tg, Nicolas O, Henrique Melo, Baruah Ps, Hunain Alam, Gary Marshall C, Young Jt, Dietrich E, Gallo D, Desjardins J, Bernier C, Fugère-Desjardins C, Tkáč J, Fournier S, Michael Zinda, Roulston A, Morris Sj, Fortin Ab, and Daniel Durocher

Subjects
Cyclin-dependent kinase 1, Cyclin E, PKMYT1, DNA synthesis, Kinase, Cancer research, FOXM1, Synthetic lethality, Biology, Mitosis
Abstract

Amplification of the gene encoding cyclin E (CCNE1) is an oncogenic driver in several malignancies and is associated with chemoresistance and poor prognosis. To uncover therapeutic targets forCCNE1-amplified tumors, we undertook genome-scale CRISPR/Cas9-based synthetic lethality screens in cellular models ofCCNE1amplification. Here, we report that increasingCCNE1dosage engenders a vulnerability to the inhibition of the PKMYT1 kinase, a negative regulator of CDK1. To inhibit PKMYT1, we developed RP-6306, an orally bioavailable and selective inhibitor that shows single-agent activity and durable tumor regressions when combined with gemcitabine in models ofCCNE1-amplification. RP-6306 treatment causes unscheduled activation of CDK1 selectively inCCNE1overexpressing-cells, promoting early mitosis in cells undergoing DNA synthesis.CCNE1overexpression disrupts CDK1 homeostasis at least in part through an early activation of the FOXM1/MYBL2/MuvB-dependent mitotic transcriptional program. We conclude that PKMYT1 inhibition is a promising therapeutic strategy forCCNE1-amplified cancers.

Published
2021

45. Childhood epidermal necrolysis and erythema multiforme major: a multicentre French cohort study of 62 patients

Author

Giraud‐Kerleroux, L., primary, Bellon, N., additional, Welfringer‐Morin, A., additional, Leclerc‐Mercier, S., additional, Costedoat, I., additional, Coquin, J., additional, Brun, A., additional, Roguedas‐Contios, A.‐M., additional, Bernier, C., additional, Milpied, B., additional, Tétart, F., additional, Du Thanh, A., additional, Cordel, N., additional, Bensaid, B., additional, Fargeas, C., additional, Tauber, M., additional, Renolleau, S., additional, Boralevi, F., additional, Ingen‐Housz‐Oro, S., additional, and Bodemer, C., additional

Published
2021
Full Text
View/download PDF

47. Drug reaction with eosinophilia and systemic symptoms (DRESS) : série de 53 cas pédiatriques français

Author

Bedouelle, E., primary, Ben Said, B., additional, Tetart, F., additional, Milpied, B., additional, Welfringer-Morin, A., additional, Maruani, A., additional, Catteau, B., additional, Dezoteux, F., additional, Staumont-Sallé, D., additional, Mazereeuw-Hautier, J., additional, Abasq, C., additional, Chiaverini, C., additional, Mahe, E., additional, Delaunay, J., additional, Mallet, S., additional, Sterling, B., additional, Puzenat, E., additional, Raynal, M., additional, Collet, E., additional, and Bernier, C., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results